In a paper published in Alzheimer’s and Dementia, a team of researchers called for more prospective studies that will look into the impact COVID-19 has on brain functioning, given the disease has been frequently associated with neurologic symptoms such as seizures and psychosis.

Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.

Acadia Pharmaceuticals Inc. announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis.

Acadia Pharmaceuticals shares dropped 22 percent after FDA commissioner Scott Gottlieb told Congress that the regulatory agency would investigate the company’s Nuplazid, which is used to treat hallucinations and psychosis related to Parkinson’s disease.

U.S. regulators approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.

After posting mixed results for its pimavanserin trial in December 2016, Acadia Pharmaceuticals is broadening its research focus from Alzheimer’s disease psychosis to the treatment of hallucinations and delusions associated with dementia-related psychosis.

A psychiatric hospital in Belgium is home to one of the world’s largest collections of human brains, which researchers say could hold the key to developing new treatments for diseases such as psychosis, schizophrenia and severe depression.

Acadia Pharmaceuticals Inc’s drug for psychosis linked to Parkinson’s disease was approved in the United States on Friday, becoming the first treatment for the condition to get a nod in the country. The U.S. Food and Drug Administration, however, asked Acadia to include a black-box warning, its strictest warning, on the drug’s label for an […]

One day after the Pfizer deal to buy Allergan was officially terminated, Allergan announced a multibillion pact with Heptares Therapeutics for neurological disorders.

Allergan Plc said on Thursday the U.S. Food and Drug Administration approved its new antipsychotic drug to treat bipolar disorder and schizophrenia. The drug, Vraylar, carries a boxed warning on increased risk of death associated with its use in older people with dementia-related psychosis, the FDA said on its website. Vraylar was approved after showing […]